Psyence BioMed Secures Supply Chain via Strategic PsyLabs Equity Investment
Psyence Biomedical Ltd. (Nasdaq: PBM) has confirmed a strategic equity investment in PsyLabs following the exercise of a pre-existing put option agreement. The transaction reinforces the vertical integration between the clinical-stage developer and its primary source of pharmaceutical-grade, nature-derived psychedelic compounds.